A 68-year-old woman with a history of unprovoked proximal DVT 18 months ago has been on rivaroxaban since diagnosis. She has no major bleeding history and has persistent risk factors (BMI 35 kg/m², limited mobility). According to current VTE guidance, what is the MOST appropriate long-term anticoagulation strategy?